EMA Backs Six Drugs, One Biosimilar for EU Approval
By Michael Mezher -
Published 10 November 2017
The European Medicines Agency (EMA) on Friday said that its Committee for Medicinal Products for Human Use (CHMP) is recommending six new drugs, a biosimilar and three generic medicines for EU approval.
Categories: News, Europe, EMA, Biologics and biotechnology, Drugs, Submission and registration
Tags: Marketing Authorization Applications, CHMP, Accelerated Assessment, Orphan Designation, Biosimilar, Jorveza, Prevymis, Ocrevus, Adynovi, Fasenra, Intrarosa, Mvasi